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quantified gait, healthy carriers of the LRRK2*G2019S
mutation had altered gait variability as compared with
healthy noncarriers, suggesting that subclinical gait
problems exist even in presymptomatic carriers.
Recently, more frequent falls were reported among
LRRK2*G2019S mutation carriers versus noncarriers,
and postural instability gait difficulties motor subtype
were found to be more common among carriers as
compared with noncarriers.17,18 We focused on the
rate of progression of the disease in carriers and non-
carriers. The diversity in the methodology of studies
does not enable comparative interpretation.
The current study has some limitations, one of which
is a small number of LRRK2*G2019S mutation carriers
and controls. We did not screen for glucocerebrosidase
(GBA) mutations that could affect outcomes and are
also common in the AJ PD population. Additionally,
although patients were examined and pull test was
determined at the “on” medication state, the time from
last levodopa intake was not taken into account.
Besides, HY3 may be a suboptimal measure of disease
progression, because it does not represent all features
that reflect milestones of disease progression, such as
time to first fall, time to becoming nurse-dependent, or
the change in UPDRS over time. Furthermore, motor
deterioration leading to loss of balance and thus HY3
also may be a consequence of normal aging, regardless
of PD progression. Therefore, that PD patients diag-
nosed at a later age may reach endpoint earlier than
patients with a younger AO is not surprising.
To better characterize the disease progression in
patients with the LRRK2*G2019S mutation, a larger,
multicenter, preferentially prospective study is needed,
using additional and alternative measures, perhaps
new biomarkers of disease progression.
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ABSTRACT
Background: Although alpha-synuclein (SNCA) is cru-
cial to the pathogenesis of Parkinson’s disease (PD)
and dementia with Lewy bodies (DLB), mutations in
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the gene appear to be rare. We have recently hypothe-
sized that somatic mutations in early development
could contribute to PD.
Methods: Expanding on our recent negative small
study, we used high-resolution melting (HRM) analysis
to screen SNCA coding exons for somatic point muta-
tions in DNA from 539 PD and DLB cerebellar sam-
ples, with two additional regions (frontal cortex,
substantia nigra) for 20 PD cases. We used artificial
mosaics to determine sensitivity where possible.
Results: We did not detect any evidence of somatic
coding mutations. Three cases were heterozygous for
known silent polymorphisms. The protocol we used was
sensitive enough to detect 5% to 10% mutant DNA.
Conclusion: Using DNA predominantly from cerebel-
lum, but also from frontal cortex and substantia nigra
(n5 20 each), we have not detected any somatic cod-
ing SNCA point mutations. VC 2014 International Parkin-
son and Movement Disorder Society
Key Words: SNCA; alpha-synuclein; somatic muta-
tion; mosaicism; etiology of Parkinson’s disease
Alpha-synuclein (SNCA), the major component of
Lewy bodies, has a key role in the pathogenesis of Parkin-
son’s disease (PD) and dementia with Lewy bodies (DLB).
Occasional copy number variants (CNV, duplications and
triplications), and five pathogenic point mutations or sin-
gle nucleotide variants (SNVs), have been reported in PD,
usually in familial cases.1 Noncoding SNCA variation is a
risk factor for sporadic PD.2 The known inherited genetic
risk factors may still account for only 10% to 20% of the
total PD risk,3 and the initiating event in SNCA aggrega-
tion is still debated. We have recently proposed in this
journal that post-zygotic somatic mutations in SNCA,
occurring in early embryogenesis, could contribute to PD,
although our pilot study was negative.4 Somatic muta-
tions can lead to the presence of more than one genetically
distinct cell in a single organism (mosaicism)5 and could
be absent in peripheral lymphocyte DNA, which is usually
analyzed. Somatic mutations have been suggested as a
cause of sporadic neurodegenerative disorders6,7 and as
an explanation of nonheritable disease in general.8 Here
we expand on our recent study,4 investigating the hypoth-
esis of somatic mutations by searching for evidence of
low-level coding SNCA point mutations in a large series
of PD and DLB brain DNA.
Materials and Methods
Samples Used
DNA from brains of 511 cases with idiopathic PD and
28 with DLB was analyzed. Patients had given informed
consent for use of their brains in research, and the study
was approved by the local ethics committee. The brain
samples originated from the Queen Square brain bank, UK
(PD, n5 339), the Parkinson’s UK Tissue bank (PD,
n5105), and the Neurological Tissue Bank of the
Biobanc-Hospital Clinic-Institut d’Investigacions Biome`di-
ques August Pi i Sunyer, Spain (n5 95, of which 67 were
PD and 28 were DLB). DNA was extracted from the cere-
bellum in all cases, using a Qiagen Blood and Tissue kit,
and additionally from the substantia nigra (SN) and frontal
cortex in 20 PD cases. The PD cases for study of all three
brain regions were chosen from the Parkinson’s UK brain
bank based on the combination of relatively short disease
duration (mean, 7.76 3 years; considered more likely to
have surviving neurons with mutations in SN4) and,
where possible, relatively early age of onset (mean,
64.16 6 years; considered more likely to have somatic
mutations6).
Laboratory Methods
We analyzed all samples using high resolution melt-
ing curve (HRM) analysis of SNCA coding exons
(numbers 2-6 for ENSEMBL transcript ID 394986)
with previously reported primers4; this allows detec-
tion of low-level mosaicism caused by somatic muta-
tions (SNV and small insertions/deletions), which
could be missed by Sanger sequencing, which is less
sensitive.9 Details are provided in Supplementary Data
online. To determine the lowest level at which a
somatic mutation would be detectable, we created
artificial mosaics by diluting DNA carrying a heterozy-
gous SNV with wild-type DNA. Dilutions down to
1:20 (i.e., 5% of DNA with heterozygous SNV, or
2.5% mutant DNA level) were studied in triplicate.
Results
We first established the sensitivity of our HRM
analysis by determining the lowest levels at which
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known pathogenic exon 3 mutations (H50Q, A53T)
could be differentiated from control DNA (Figure 1a,
b). The HRM analysis showed that mutant DNA pro-
portions of at least 5% (equivalent to 10% of cells
from a sample carrying a heterozygous somatic SNV)
were differentiated from controls. Detection of the
G51D mutation10 allowed us to subsequently confirm
that this could be differentiated at a level of 5% (Fig-
ure 1c). In all of these cases, even a 2.5% level of
mutation gave a minimal difference, but this probably
would have been detected only in H50Q. Sequencing
of artificial mosaics for selected SNVs confirmed the
superiority of HRM over sequencing for low-level
mutations (Supplemental Data Figure 1).
Coding exons were amplified and analyzed by HRM
in all samples in duplicate. Samples in which at least
one of the replicates showed an aberrant melt curve
were analyzed with HRM in additional duplicate or
more reactions, and a polymerase chain reaction prod-
uct with the apparent shift was sequenced bidirection-
ally. Only three samples showed clear melting curve
shifts; sequencing of these did not reveal somatic
mutations, but heterozygosity for synonymous silent
polymorphic SNVs already present in dbSNP;
rs76642636 (exon 6, c.324C>T) in two cases, and
rs144758871 (exon 4, c.216G>A) in one (Figure 2).
Although even silent SNVs could have biologically
important effects,11 the very low frequency of these
SNVs, both in our patient cohort and in the popula-
tion (0.4% and 0.07%, in European and African
American controls, respectively, in the Washington
Exome server database, http://evs.gs.washington.edu/
EVS/), does not allow any conclusions on whether
they might modulate PD risk. Having detected these
SNVs, however, we then used them to create artificial
mosaics to determine the sensitivity of HRM for a low
percentage of these changes too; detection of 10%
variant DNA level was possible, but lower levels could
not be reliably differentiated (Figure 2).
No additional consistent melting curve shifts were
detected. We considered the possibility that subtle
HRM shifts could indicate mutations at levels below
Sanger sequencing sensitivity. However, in no cases
did a sample give a consistently aberrant profile for a
particular exon, which would have suggested that
possibility.
FIG. 1. Estimation of sensitivity of HRM for detection of low levels of exon 3 SNV. A: H50Q, B: A53T, C: G51D. The undiluted heterozygous sample
(50% mutation) is blue and identified by arrows, and lower levels of mutations are 20% (red), 10% (green), 5% (orange), 2.5% (purple, identified by
arrowheads). Controls are shown in gray. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Discussion
We report the largest series of PD and DLB brain-
derived DNA analyzed for somatic SNCA coding
mutations. We studied 539 DNA samples from cere-
bellum, and in 20 PD cases, also SN and frontal cor-
tex, using HRM, which has proven sensitivity for low-
level somatic mutations. No somatic mutations were
identified. Known heterozygous silent SNVs, not lead-
ing to amino acid changes, accounted for the only
consistent HRM abnormalities. We demonstrated that
several SNVs could be confidently detected by our
protocol at mutation level 5% or lower in exon 3
(where 4 of 5 missense mutations are located), and
10% for exons 4 and 6, in line with the known sensi-
tivity of HRM; we expect to have achieved similar
sensitivity for other exons, although we could not test
that because of lack of positive controls. We can
therefore confidently exclude a moderate level of
mosaicism (10% level of mutant DNA, or 20% cells
with a heterozygous mutation, and even lower for
exon 3) for SNCA coding mutations (SNVs and small
insertions or deletions) in the brain regions analyzed.
Our technique was not designed to detect even lower
level coding somatic mutations, which could still be
important, however, because they could act as the seed
from which pathological conditions spread in a prion-
like fashion,3 noncoding mutations, or CNVs. The pos-
sibility of somatic mutations in other regions could not
be excluded, because sampling bias could underlie nega-
tive results,3 although for 20 cases we analyzed three
regions, including the SN. The SN may be the most rele-
vant region, because it is very heavily affected in PD,
and therefore any somatic mutations should be present
there3; conversely, however, SN neurons with somatic
mutations should be the most vulnerable, and therefore
could be lost long before the patient dies. The cell line-
age of the brain is still very poorly understood,3 but
most brain cell types show little clonal clustering, sug-
gesting that cells with somatic mutations in early devel-
opment could be widely dispersed and present at low
levels in any given region12; therefore the cerebellum,
where neurons are not significantly lost in PD, although
some SNCA accumulation is present,13 could also allow
detection of putative very early somatic mutations pres-
ent in neurons of a shared lineage dispersed throughout
the nervous system.
The results of this large study, in conjunction with
our recent smaller study, provide evidence against
somatic SNCA coding SNVs (at levels of at least 5-
10%) being a major cause of PD. Although advances in
next-generation sequencing allow the detection of ever-
decreasing levels of SNVs, we believe that further
efforts to detect somatic mutations in PD should focus
on other kinds of genomic changes. The de novo muta-
tion rate for CNV can be two to four orders of magni-
tude higher than for SNV,14 with CNVs arising in
mitosis, explaining the increasing evidence for CNV
mosaicism in healthy humans, including the brain.15-17
FIG. 2. Estimation of sensitivity of HRM for detection of low levels of SNV in other exons. A: rs144758871 (exon 4), B: rs76642636 (exon 6). The
undiluted heterozygous sample (50% SNV) is blue, and SNV levels in diluted samples are 20% (red), 10% (green), 5% (orange), 2.5% (purple). Con-
trols are shown in gray. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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This was elegantly demonstrated in single frontal corti-
cal neurons, which frequently harbor somatic
CNVs.18,19 Both SNCA and PARK2 may be particu-
larly susceptible to somatic CNV generation, because
they are in chromosomal fragile sites.4,20 The concept
of widespread mosaicism is gaining ground,8,21,22 and a
substantial proportion of the risk of sporadic diseases
may be explained by nonheritable somatic genomic var-
iation, possibly in genes involved in Mendelian forms of
the same disease.8 Another common sporadic disease
with complex genetics, hypertension can be attributable
to somatic mutations in genes involved in aldosterone
production, with a more severe phenotype in inherited
cases.23-25 Because most PD risk remains unexplained,
further analysis for somatic mutations could advance
our understanding of sporadic PD pathogenesis, but evi-
dence has yet to be provided to support this hypothesis,
and we must acknowledge the potential that this con-
cept is not relevant to PD.
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ABSTRACT
Background and objective: Progression of Parkinson’s
disease (PD) is frequently characterized by the occur-
rence of freezing of gait (FOG) representing a disabling
motor complication. We aim to investigate safety and
efficacy of transcranial direct current stimulation of the
primary motor cortex of PD patients with FOG.
Methods: In this cross-over, double-blind, sham-
controlled study, 10 PD patients with FOG persisting in
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